Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Spotlight Correspondence
  • Published:

Ph-positive and -negative myeloproliferative syndromes may co-exist

Leukemia volume 18, pages 1305–1307 (2004)Cite this article

TO THE EDITOR

Current thinking holds that the acquisition of the Philadelphia (Ph) translocation in a normal hematopoietic stem cell initiates chronic myelogenous leukemia (CML). Thus, suppression of the Ph-positive clone should re-establish normal hematopoiesis. Recently, chromosomal abnormalities in Ph-negative cells were observed in CML patients with cytogenetic response to imatinib, sometimes associated with myelodysplasia, raising doubts as to the ‘normality’ of the Ph chromosome-negative hematopoiesis in CML.1, 2, 3, 4, 5, 6, 7 Here, we describe a patient with coexistence of Ph-positive and Ph-negative myeloproliferative syndromes (MPS).

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1

References

  1. Bumm T, Muller C, Al Ali HK, Krohn K, Shepherd P, Schmidt E et al. Emergence of clonal cytogenetic abnormalities in Ph-cells in some CML patients in cytogenetic remission to imatinib but restoration of polyclonal hematopoiesis in the majority. Blood 2003; 101: 1941–1949.

    Article  CAS  Google Scholar 

  2. Andersen MK, Pedersen-Bjergaard J, Kjeldsen L, Dufva IH, Brondum-Nielsen K . Clonal Ph-negative hematopoiesis in CML after therapy with imatinib mesylate is frequently characterized by trisomy 8. Leukemia 2002; 16: 1390–1393.

    Article  CAS  Google Scholar 

  3. Schoch C, Haferlach T, Kern W, Schnittger S, Berger U, Hehlmann R et al. Occurrence of additional chromosome aberrations in chronic myeloid leukemia patients treated with imatinib mesylate. Leukemia 2003; 17: 461–463.

    Article  CAS  Google Scholar 

  4. Meeus P, Demuynck H, Martiat P, Michaux L, Wouters E, Hagemeijer A . Sustained, clonal karyotype abnormalities in the Philadelphia chromosome negative cells of CML patients successfully treated with imatinib. Leukemia 2003; 17: 465–467.

    Article  CAS  Google Scholar 

  5. Royer-Pokora B, Hildebrandt B, Redmann A, Herold C, Kronenwett R, Haas R et al. Simultaneous occurrence of a t(9;22) (Ph) with a t(2;11) in a patient with CML and emergence of a new clone with the t(2;11) alone after imatinib mesylate treatment. Leukemia 2003; 17: 807–810.

    Article  CAS  Google Scholar 

  6. Chee YL, Vickers MA, Stevenson D, Holyoake TL, Culligan DJ . Fatal myelodysplastic syndrome developing during therapy with imatinib mesylate and characterised by the emergence of complex Philadelphia negative clones. Leukemia 2003; 17: 634–635.

    Article  CAS  Google Scholar 

  7. O'Dwyer ME, Gatter KM, Loriaux M, Druker BJ, Olson SB, Magenis RE et al. Demonstration of Philadelphia chromosome negative abnormal clones in patients with chronic myelogenous leukemia during major cytogenetic responses induced by imatinib mesylate. Leukemia 2003; 17: 481–487.

    Article  CAS  Google Scholar 

  8. Blickstein D, Aviram A, Luboshitz J, Prokocimer M, Stark P, Bairey O et al. BCR-ABL transcripts in bone marrow aspirates of Philadelphia-negative essential thrombocytopenia patients: clinical presentation. Blood 1997; 90: 2768–2771.

    CAS  PubMed  Google Scholar 

  9. Emilia G, Marasca R, Zucchini P, Temperani P, Luppi M, Torelli G et al. BCR-ABL rearrangement is not detectable in essential thrombocythemia. Blood 2001; 97: 2187–2189.

    Article  CAS  Google Scholar 

  10. Martiat P, Ifrah N, Rassool F, Morgan G, Giles F, Gow J et al. Molecular analysis of Philadelphia positive essential thrombocythemia. Leukemia 1989; 3: 563–565.

    CAS  PubMed  Google Scholar 

  11. Ganti AK, Potti A, Mehdi SA . Chromosomal anomalies in two coexistent myeloproliferative disorders. Cancer Genet Cytogenet 2003; 145: 172–175.

    Article  CAS  Google Scholar 

  12. Daley GQ, Van Etten RA, Baltimore D . Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome. Science 1990; 247: 824–830.

    Article  CAS  Google Scholar 

  13. Fialkow PJ, Martin PJ, Najfeld V, Penfold GK, Jacobson RJ, Hansen JA . Evidence for a multistep pathogenesis of chronic myelogenous leukemia. Blood 1981; 58: 158–163.

    CAS  PubMed  Google Scholar 

  14. Raskind WH, Ferraris AM, Najfeld V, Jacobson RJ, Moohr JW, Fialkow PJ . Further evidence for the existence of a clonal Ph-negative stage in some cases of Ph-positive chronic myelocytic leukemia. Leukemia 1993; 7: 1163–1167.

    CAS  PubMed  Google Scholar 

  15. Spencer A, Granter N . Leukemia patient-derived lymphoblastoid cell lines exhibit increased induction of leukemia-associated transcripts following high-dose irradiation. Exp Hematol 1999; 27: 1397–1401.

    Article  CAS  Google Scholar 

  16. Vickers M . Estimation of the number of mutations necessary to cause chronic myeloid leukaemia from epidemiological data. Br J Haematol 1996; 94: 1–4.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Center for Hematologic Malignancies, Oregon Cancer Institute, Oregon Health & Science University, Portland, OR, USA

    M J Mauro, M Loriaux & M W Deininger

Authors
  1. M J Mauro
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. M Loriaux
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. M W Deininger
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to M W Deininger.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Mauro, M., Loriaux, M. & Deininger, M. Ph-positive and -negative myeloproliferative syndromes may co-exist. Leukemia 18, 1305–1307 (2004). https://doi.org/10.1038/sj.leu.2403375

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.leu.2403375

Search

Advanced search

Quick links